Compare Tenet Healthcare Corporation (THC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tenet Healthcare Corporation vs Zoetis Inc — how do they compare? Tenet Healthcare Corporation trades at $260 (market cap $20.98B), while Zoetis Inc trades at $73.27 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tenet Healthcare Corporation for 15 Days and Zoetis Inc for 70 Days on average.
| THC | ZTS | |
|---|---|---|
Market Cap | $20.98B | $30.20B |
Volume | 428,008 | 6,175,327 |
Sector | Health | Health |
52-Week High | $280.77 | $147.53 |
52-Week Low | $161.37 | $69.09 |
Typical Hold Time | 15 Days | 70 Days |
Enterprise Value | $32.06B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tenet Healthcare (THC) trades at $259.83, up 0.53% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 53.31%, net margin 9.9%). Recent news highlights strong cash flow supporting capital returns and upcoming Q3 2026 results on October 29. Valuation appears reasonable with P/E of 10.07 and EV/EBITDA of 5.75.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and 7% upside to consensus target of $283.36. Key catalysts include sustained earnings momentum and efficient capital allocation. Risks include surgical volume pressures and cash flow sustainability concerns amid aggressive buybacks. The stock's current technical setup near pivot point $259 suggests balanced risk-reward.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.
Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
